Okami Medical focused this week on expanding awareness and clinical adoption of its HDBRAID vascular occlusion platform and LOBO product line. The company used social media to spotlight an educational lunch symposium planned for the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The symposium, scheduled for April 11 at SIR 2026, is framed as a case-based learning event featuring three experienced implanters. These physicians are expected to present a range of real-world cases and emphasize what Okami describes as the HDBRAID difference in vascular occlusion procedures.
By positioning the session at a major specialty conference and targeting interventional radiologists, Okami Medical appears to be pursuing deeper clinical engagement with key procedural decision makers. The educational format and focus on peer-to-peer discussion aim to build familiarity and confidence with both the HDBRAID technology and LOBO devices.
Several posts suggest the company views this symposium as a channel-building initiative that could support broader adoption over time. Strong visibility at SIR 2026 may help Okami reach high-volume users, potentially supporting procedure growth and reinforcing its competitive stance in embolization and occlusion devices.
In addition to conference promotion, Okami highlighted a specific clinical case involving its LOBO-9 device. A clinician reportedly used a single LOBO-9 to occlude a 7.7 mm collateral vessel during endovascular repair of an iliac artery aneurysm, achieving successful occlusion via a 6 Fr Ansel sheath.
This case example underscores the device’s usability and performance in complex vascular procedures and suggests a growing real-world evidence base around the LOBO platform. Such cases may support physician adoption and could prove important in reimbursement discussions and broader market acceptance.
Taken together, this week’s activity reflects Okami Medical’s emphasis on clinical education, evidence generation, and targeted engagement with interventional radiologists. These efforts may help strengthen the company’s long-term position in the vascular occlusion market if they translate into sustained utilization and wider clinical endorsement.